nPhase Raises $30M in Series D Funding Led by Viking Global Investors

nPhase, Inc., an Atlantic Beach, FL-based provider of an AI-native clinical data platform, has raised $30 million in a Series D funding round led by Viking Global Investors.

The company will use the funding to expand its agentic AI capabilities and develop intelligent workflows that help clinical research teams manage and process data more efficiently.

What is nPhase?

nPhase develops technology for managing clinical trial and real-world data. Its flagship platform, nPhase.ai, brings clinical data together in one system for pharmaceutical companies and contract research organisations (CROs).

Read More:Northwood Space Secures $375M in Series C Funding

The platform combines two products: the Unified Data Management System (UDMS) and the Statistical Computing Environment (SCE). Together, they connect different stages of clinical research, from study setup, and data collection to analysis and regulatory submission.

Clinical trial data often comes from multiple sources, including research sites, laboratories, patients and digital health sensors. These sources can operate through separate systems, creating manual work and delays.

nPhase.ai brings this information into a governed environment, where data is continuously standardised, processed and validated. This helps research teams monitor trial safety and operational signals without waiting for traditional batch processing.

How Much Funding Has nPhase Raised?

nPhase has raised $30 million in its latest Series D funding round. The company has not disclosed its total funding raised or details of previous funding rounds.

Who Invested in nPhase’s Series D?

Viking Global Investors led the $30 million Series D round. No other participating investors were named in the announcement.

Why the Funding Matters

nPhase will use the capital to accelerate the next phase of development of its agentic AI capabilities.

The company plans to expand intelligent workflows that can take on operational tasks across the clinical data lifecycle. Its aim is to help research teams reduce manual processes and make better use of clinical data.

Who founded nPhase?

nPhase was founded by Scott Climes, and Jaya Prakash Rao. The company is headquartered in Atlantic Beach, Florida.

“We’re proud to have earned the confidence of Viking Global Investors, whose deep expertise in life sciences and enterprise technology makes them an ideal strategic partner,” said Scott Climes, CEO of nPhase, Inc. “We’ve built the unified, governed data foundation that makes AI possible across the clinical data lifecycle.

Market and Business Growth

The company recently launched its nPhase.ai clinical data platform, which combines UDMS and SCE into a unified system.

The platform is designed to support pharmaceutical sponsors and CROs throughout the clinical research process, from data acquisition to regulatory submission.

nPhase says its system can reduce certain data processing and analysis workflows from four or more months to weeks. It also supports near real-time data validation and monitoring.

What Happens Next?

nPhase plans to expand its agentic AI capabilities and build more intelligent workflows across clinical research operations. The company will focus on helping pharmaceutical sponsors and CROs manage clinical data through a connected platform while keeping human experts in control of key decisions.

Read More:Wrapped Health Secures $2.1M in Pre-Seed Funding